SCHEMBL4756479

SCHEMBL4756479

Cc1nn(-c2cnccn2)c(C)c1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH1 Q13686 1/20 0.45
LMNA P02545 1/20 0.45
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
KDM4E B2RXH2 3/20 0.40
NAPRT Q6XQN6 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
POLB P06746 4/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
MAPT P10636 4/20 0.37
RAB9A P51151 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PDE4D Q08499 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269737 0.82 PDE4D (0.56) KDM4EMAPTPDE4D
SCHEMBL27780413 0.79 ALDH1A1 (0.51) ALKBH1LMNACCNA2CDK2KDM4E
SCHEMBL13600098 0.77 CA12 (0.44) LMNACCNA2CDK2KDM4ECYP1A2
SCHEMBL15180443 0.76 ALKBH1 (0.48) ALKBH1LMNACCNA2CDK2KDM4E
SCHEMBL26659276 0.74 ALKBH1 (0.59) ALKBH1LMNAKDM4EPOLBCYP1A2
SCHEMBL13600097 0.74 CCNA2 (0.41) LMNACCNA2CDK2KDM4ECYP1A2
SCHEMBL20027612 0.73 KDM5A (0.43) CCNA2CDK2KDM4ENAPRTHCAR2
SCHEMBL13607159 0.72 LMNA (0.47) ALKBH1LMNAPOLBCYP1A2CYP2C9
SCHEMBL13741414 0.71 CCNA2 (0.41) CCNA2CDK2KDM4ECYP1A2MAPT
SCHEMBL28318778 0.71 LMNA (0.52) ALKBH1LMNAPOLBEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1987036-A1 HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2008-11-05 EP disclosed
WO-2007093520-A1 HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 WO disclosed
US-20070191335-A1 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease ROCHE PALO ALTO LLC 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191335-A1 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease CCR5, CXCR1, CXCR3 ALKBH1 862/4885LMNA 4654/4885CCNA2 2753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.